Company Overview
Recursion Pharmaceuticals, Inc. operates as a clinical-stage biotechnology entity dedicated to decoding biology and chemistry by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery in the United States and the United Kingdom. This operational focus places the company squarely within the Healthcare sector, specifically the Biotechnology industry, which typically involves high-risk, high-reward research and development cycles aimed at advancing therapeutic options. The organization employs a workforce of 600 individuals and holds a market capitalization of $1.74B, generating annual revenue of $74.68M. These financial metrics indicate that the company is a mid-cap entity with significant revenue growth but currently operates without profitability, relying on its substantial cash reserves to fund its industrialization of drug discovery efforts and ongoing clinical-stage operations.
Financial Health
The company reported revenue of $74.68M for the trailing twelve months, yet posted a net income of $-644,758,976 and an EBITDA of $-564,430,976. The substantial gap between the positive revenue of $74.68M and the negative net income reveals a cost structure where operating expenses, likely driven by research, development, and automation infrastructure, vastly exceed total sales. Free cash flow stands at $-208,521,744, indicating that the company is consuming cash at a significant rate to fund its growth initiatives rather than generating surplus liquidity from operations. All three margin metrics reflect this pre-profitability status, with a Gross Margin of 0.0%, an Operating Margin of -328.8%, and a Profit Margin of 0.0%. The negative operating margin specifically highlights that operating expenses are more than three times the level of revenue generated. On the balance sheet, the company holds $743.29M in cash against $77.97M in debt, resulting in a debt-to-equity ratio of 6.89. Despite the elevated debt-to-equity ratio, the liquidity position is robust given the cash on hand significantly outweighs obligations. The current ratio of 5.50 suggests strong short-term liquidity, as current assets are more than five times current liabilities. Furthermore, the Return on Equity is -59.5% and the Return on Assets is -27.7%, metrics that reveal management is currently utilizing shareholder capital and assets to generate losses rather than positive returns, a common characteristic in early-stage biotechnology firms.
Valuation Assessment
Valuation metrics for Recursion Pharmaceuticals present a complex picture due to the lack of earnings, with a P/E Ratio (TTM) listed as N/A and a Forward P/E of -3.86. The disparity between the unavailable trailing P/E and the negative forward P/E implies that the market is pricing the stock based on future potential earnings rather than current performance, as current earnings are insufficient to calculate a standard multiple. The Price to Book ratio is 1.53, suggesting the market values the company at a premium of 53% above its book value, which may reflect intangible assets like data platforms and intellectual property not fully captured on the balance sheet. Alternative valuation metrics such as the Price to Sales ratio of 23.23 and an EV/EBITDA of -1.86 further indicate that investors are valuing the firm primarily on its revenue generation potential and technology platform rather than immediate profitability. In terms of trading range, the stock has a 52-Week High of $7.18 and a 52-Week Low of $2.98. Based on the provided data points, the specific current trading price is not explicitly defined to calculate an exact percentage below the high, but the valuation range sits within this established band. The Beta is 0.96, which indicates that the stock's price volatility is roughly in line with the broader market, showing neither significant amplification nor dampening of market movements.
Growth & Income
Revenue Growth (YoY) is reported at 681.7%, while Earnings Growth (YoY) is N/A. The absence of a calculable earnings growth rate alongside the massive revenue expansion implies that the company is in a revenue scaling phase where earnings have not yet materialized to track with top-line growth. As a non-dividend payer, the company does not distribute a Dividend Yield or a Payout Ratio, as both are N/A or 0.0%, meaning the company reinvests all available earnings and cash flows directly into research, development, and operational scaling rather than returning capital to shareholders. This reinvestment strategy is typical for clinical-stage biotechnology companies that prioritize asset building over income generation. The overall growth and income profile is characterized by exceptional revenue expansion and a complete absence of dividends or current earnings, reflecting a capital-intensive business model focused on long-term therapeutic development.